~~<i id='EAF819980B'><strike id='EAF819980B'><tt id='EAF819980B'><pre id='EAF819980B'></pre></tt></strike></i>~~

Home» knowledge» explore

explore

author：knowledge 2025-09-29 18:02:26 Page View：5

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： PBM reform efforts get punted in Congress
Next article： The high cost of giving birth even with insurance

focus

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

DarronCummings/APEliLillysaidFridaythatitwillacquireDermira,asmallbiotechdevelopingdrugsforchronicsk

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

STAT Boddities: What happens to the brain when we get scared?

Whydowegasp,jumpandgopalewhenwe'refrightened?Itallcomesdowntoatiny,almond-shapedstructureinthebraint

WSS

explore

explore

leisure time

focus

STAT Boddities: What happens to the brain when we get scared?